ClinicaliQ Trial Snapshot
- Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease — Recruiting • Phase II • NCT06989359.
- Drug being tested: ADX-038, a novel therapeutic agent targeting complement-mediated pathways, is being evaluated for safety, efficacy, and how the body processes and responds to the drug (PK/PD) in adult patients with complement-mediated kidney diseases.
- Patient eligibility: The study focuses on adult patients with confirmed complement-mediated kidney disease; specific inclusion/exclusion criteria would determine baseline kidney function, disease activity, and prior treatment requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Eligibility Snapshot
- : * Mean eGFR greater than or equal to 30 mL/min/1.73m2 * Clinical evidence of active kidney disease * Treated with supportive care including an ACE inhibitor or ARB if applicable * Willing to receive required vaccinations * Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.